Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 6/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | SOD3 | P08294 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17526509 | 1.00 | GNAO1 (0.45) | GNAO1GNAI3GNAI1CXCR4SIGMAR1 | |
| SCHEMBL17526676 | 0.98 | GNAO1 (0.47) | GNAO1GNAI3GNAI1CXCR4SIGMAR1 | |
| SCHEMBL17526616 | 0.98 | GNAO1 (0.47) | GNAO1GNAI3GNAI1CXCR4SIGMAR1 | |
| SCHEMBL17526971 | 0.97 | GNAO1 (0.49) | GNAO1GNAI3GNAI1CXCR4SIGMAR1 | |
| SCHEMBL17526841 | 0.97 | GNAO1 (0.49) | GNAO1GNAI3GNAI1CXCR4SIGMAR1 | |
| SCHEMBL15187325 | 0.95 | SIGMAR1 (0.43) | GNAO1GNAI3GNAI1CXCR4SIGMAR1 | |
| SCHEMBL15187332 | 0.95 | SIGMAR1 (0.43) | GNAO1GNAI3GNAI1CXCR4SIGMAR1 | |
| SCHEMBL3148550 | 0.90 | SIGMAR1 (0.42) | GNAO1GNAI3GNAI1CXCR4SIGMAR1 | |
| SCHEMBL31510341 | 0.88 | GNAO1 (0.44) | GNAO1GNAI3GNAI1CXCR4SIGMAR1 | |
| SCHEMBL17523860 | 0.85 | CXCR4 (0.43) | GNAO1GNAI3GNAI1CXCR4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | GNAO1 4461/4885GNAI3 2852/4885GNAI1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.